According to a new clinical study,
Boston Scientific Corporation
) Vercise Deep Brain Stimulation (DBS) System possesses a
therapeutic edge on grounds of a distinctive ability to treat
patients suffering from Parkinson's disease.
Results of the Boston Scientific CUSTOM-DBS study were presented
at the 18th International Congress of Parkinson's Disease and
Movement Disorders in Stockholm, Sweden. It involved 15 patients
who were previously implanted with the Vercise DBS system. These
patients were examined using test and control pulse widths.
DBS is a surgical treatment method involving the placement of a
device that stimulates specific areas of the brain using electrical
signals, and in turn, helps in controlling Parkinson's disease
The Vercise DBS System is the only commercially available
platform designed to generate stimulation pulses at shorter width
settings, which provide larger therapeutic windows. Therapeutic
window refers to the range of electrical currents that can provide
effective treatment without bringing about any side effect..
As per the CUSTOM-DBS study, shorter stimulation pulses have a
potential clinical advantage over conventional DBS therapy. This is
because larger therapeutic windows results in avoidance of
stimulation-related side effects and offer effective therapy.
In the CUSTOM-DBS study, shorter electrical pulses compared to
conventional settings were used to stimulate the patients' DBS
implants. In order to compare the two settings, the standard UPDRS
III score assessment for Parkinson's disease was used to estimate
the stimulation efficacy.
The study results also revealed that the shorter pulse width
settings with the Vercise System require less electrical energy to
achieve optimal therapy. This indicates that there may also be
energy efficiency advantages when using these settings.
According to reliable sources, the CUSTOM-DBS study
distinguishes the Vercise DBS System from all other comparable
technologies, as having the ability to provide better patient
outcomes through this new stimulation approach, using shorter
electrical pulses. This also happens to be one of the first studies
that offer Level I evidence of a clinical advantage to specific
deep brain stimulation settings, such as shorter pulse widths.
Boston Scientific is an innovation leader in implantable DBS
technology. The Vercise DBS System possesses both CE Mark and TGA
(Australia Therapeutic Goods Administration) approval and is
available for sale in Europe, Israel, Australia and select
countries in Latin America for Parkinson's disease. It also has CE
Mark approval for intractable primary and secondary dystonia.
In the U.S., the Vercise DBS System is under investigation at
present and is not yet available for use or sale. The INTREPID
clinical trial began enrolment in the U.S. in mid-2013 to estimate
the safety and effectiveness of the Vercise DBS System in treating
patients having Parkinson's disease.
Boston Scientific currently carries a Zacks Rank #3 (Hold). Some
better-ranked medical product stocks that warrant a look include
Eagle Pharmaceuticals Inc.
). All the three stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
BOSTON SCIENTIF (BSX): Free Stock Analysis
EAGLE PHARMACT (EGRX): Free Stock Analysis
NEUROMETRIX INC (NURO): Free Stock Analysis
CARDICA INC (CRDC): Free Stock Analysis Report
To read this article on Zacks.com click here.